Analyst Activity – Morgan Stanley Reiterates Overweight on NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)

Analyst Ratings For NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)

Story continues below

Today, Morgan Stanley reiterated its Overweight rating on NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO) with a price target of $200.00.

Some recent analyst ratings include

  • 6/4/2018-Morgan Stanley Reiterated Rating of Overweight.
  • 6/4/2018-William Blair Reiterated Rating of Buy.
  • 5/30/2018-Piper Jaffray Companies initiated coverage with a Overweight rating.
  • 5/17/2018-BTIG Research Reiterated Rating of Buy.


  • On 5/15/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $136.51 per share and the total transaction amounting to $2,047,650.00.
  • On 5/15/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $137.42 per share and the total transaction amounting to $423,528.44.
  • On 4/25/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $131.12 per share and the total transaction amounting to $1,966,800.00.
  • On 4/25/2018 Naarden Jacob Van, Insider, sold 3,082 with an average share price of $131.23 per share and the total transaction amounting to $404,450.86.
  • On 4/24/2018 Jennifer Burstein, VP, sold 1,700 with an average share price of $131.65 per share and the total transaction amounting to $223,805.00.
  • On 4/20/2018 Lori Anne Kunkel, Director, sold 5,000 with an average share price of $132.68 per share and the total transaction amounting to $663,400.00.
  • On 3/14/2018 Joshua H Bilenker, CEO, sold 15,000 with an average share price of $131.54 per share and the total transaction amounting to $1,973,100.00.

Recent Trading Activity for NASDAQ:LOXO – Loxo Oncology (NASDAQ:LOXO)
Shares of NASDAQ:LOXO – Loxo Oncology closed the previous trading session at 189.11 up +2.42 1.30% with shares trading hands.

An ad to help with our costs